Insider Buying: Enovis (NYSE:ENOV) Insider Acquires $50,008.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 2,660 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were bought at an average price of $18.80 per share, with a total value of $50,008.00. Following the completion of the acquisition, the insider owned 63,898 shares of the company’s stock, valued at $1,201,282.40. This trade represents a 4.34% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The shares were bought at an average cost of $20.32 per share, with a total value of $49,946.56.
• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The stock was purchased at an average cost of $19.46 per share, for a total transaction of $100,024.40.
• On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average price of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was acquired at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Trading Down 3.2%

Shares of NYSE:ENOV opened at $18.43 on Friday. Enovis Corporation has a 1 year low of $18.23 and a 1 year high of $34.28. The firm has a fifty day moving average price of $25.32 and a 200 day moving average price of $24.13. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $1.06 billion, a PE ratio of -0.96 and a beta of 1.31.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ENOV shares. Wells Fargo & Company dropped their target price on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price target on Enovis in a research report on Tuesday, September 1st. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Evercore set a $32.00 target price on Enovis in a research note on Monday, July 6th. Finally, UBS Group reaffirmed a “buy” rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis during the second quarter valued at about $39,000. IFP Advisors Inc grew its position in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares in the last quarter. Allworth Financial LP increased its stake in Enovis by 59.7% during the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock valued at $36,000 after acquiring an additional 652 shares during the period. Amundi increased its stake in Enovis by 397.7% during the second quarter. Amundi now owns 369,189 shares of the company’s stock valued at $7,642,000 after acquiring an additional 295,005 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Enovis in the 2nd quarter valued at approximately $559,000. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.